324 studies found for:    biogen | biogen
Show Display Options
RSS Create an RSS feed from your search for:
biogen | biogen
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Recruiting A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
Condition: Healthy
Interventions: Drug: BG00012 (dimethyl fumarate) - Reference form;   Drug: BG00012 (dimethyl fumarate) - Test form
4 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
5 Recruiting BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: BIIB023;   Biological: Placebo;   Drug: Mycophenolate Mofetil;   Drug: Oral corticosteroid regimen
6 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor IX Protein (Known as rFIXFc) in Untreated Males With Severe Hemophilia B
Condition: Hemophilia B
Intervention: Biological: BIIB029 (rFIXFc)
7 Not yet recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BIIB031 (rFVIIIFc)
8 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo;   Biological: baminercept alfa;   Biological: Baminercept alfa
9 Recruiting BIIB017 (PEGylated Interferon Beta-1a) Related Flu-Like Symptoms in Relapsing Multiple Sclerosis Participants
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: BIIB017 (Peginterferon beta-1a);   Drug: Naproxen
10 Recruiting A Study Evaluating the Effectiveness of Tecfidera™ (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate (DMF)
11 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
12 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
13 Active, not recruiting Extension Study to Evaluate Safety and Efficacy of BG00002 (Natalizumab) in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: BG00002 (natalizumab)
14 Completed Natalizumab (BG00002, Tysabi) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis
Interventions: Drug: Natalizumab;   Drug: Placebo
15 Active, not recruiting 215ON201 BIIB033 In Acute Optic Neuritis (AON)
Condition: Acute Optic Neuritis
Interventions: Biological: BIIB033;   Drug: Placebo
16 Completed JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention:
17 Completed Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: BG00002
18 Completed BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BG00012 (dimethyl fumarate);   Drug: Glatiramer Acetate;   Drug: Interferon beta 1a
19 Completed Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Low-Grade
Intervention: Drug: ibritumomab tiuxetan (Zevalin®)
20 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years